	US 12,343,361 B2
	Compositions and methods for the treatment of hepatic diseases and disorders
Elizabeth McKenna, Houston, TX (US)
Assigned to Labyrinth Holdings, LLC, Sugar Land, TX (US)
Filed by Labyrinth Holdings, LLC, Houston, TX (US)
Filed on Jan. 6, 2023, as Appl. No. 18/151,205.
Application 18/151,205 is a continuation of application No. 16/172,825, filed on Oct. 28, 2018, granted, now 11,857,577.
Application 16/172,825 is a continuation of application No. 15/626,055, filed on Jun. 16, 2017, granted, now 10,149,869, issued on Dec. 11, 2018.
Application 15/626,055 is a continuation of application No. 13/743,194, filed on Jan. 16, 2013, granted, now 9,713,630, issued on Jul. 25, 2017.
Claims priority of provisional application 61/586,975, filed on Jan. 16, 2012.
Prior Publication US 2023/0372410 A1, Nov. 23, 2023
Int. Cl. A61K 35/74 (2015.01); A61K 9/00 (2006.01); A61K 9/68 (2006.01); A61K 35/742 (2015.01); A61K 35/744 (2015.01); A61K 38/48 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 35/742 (2013.01); A61K 35/744 (2013.01); A61K 38/482 (2013.01); C12Y 304/21043 (2013.01); A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); Y02A 50/30 (2018.01)]

19 Claims

1. A liquid formulation comprising:

(a) a lysate and/or cell wall extract from a Gram-positive bacterium comprising an active ingredient that is a toll-like receptor (TLR) ligand that activates at least one or more TLRs or Nod-like receptors (NLRs), or a pharmaceutically acceptable salt thereof; and

(b) a buffer;

wherein the liquid formulation is formulated for oral or nasal delivery; and

wherein the liquid formulation is formulated to provide a controlled and sustained release of the active ingredient in a therapeutically effective amount for greater than 1 minute after administration.